Results 21 to 30 of about 6,360,422 (309)

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Alzheimer’s Research & Therapy, 2019
Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR) and Marguerite RoAD (MR) phase 3
Gregory Klein, Paul Delmar, Nicola Voyle, Sunita Rehal, Carsten Hofmann, Danielle Abi-Saab, Mirjana Andjelkovic, Smiljana Ristic, Guoqiao Wang, Randall Bateman, Geoffrey A. Kerchner, Monika Baudler, Paulo Fontoura, Rachelle Doody   +13 more
doaj   +1 more source

Optimization of Baseplate Hub Design for Swaging Operation

Journal of Advanced Mechanical Design, Systems, and Manufacturing, 2010
Swaging process is studied through a 2-D axisymmetric finite element model with non-linear material models and allowing large deformation. The effects of major baseplate hub geometrical parameters are studied for the case of a single actuator arm with ...
K.C. EE, Peter HAHN, Brett HOLAWAY
doaj   +1 more source

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning

Bioengineering, 2022
Improving productivity to reduce the cost of biologics manufacturing and ensure that therapeutics can reach more patients remains a major challenge faced by the biopharmaceutical industry.
Qin He, Matthew S. Rehmann, Jun Tian, Jianlin Xu, Luzmary Sabino, Erik Vandermark, Ziev Basson, Iris Po, Kathleen Bierilo, Gabi Tremml, Giovanni Rizzi, Erik F. Langsdorf, Nan-Xin Qian, Michael C. Borys, Anurag Khetan, Zheng-Jian Li   +15 more
doaj   +1 more source

Two grass pollen tablets commercially available for allergy immunotherapy display different IgE epitope repertoires

Clinical and Translational Allergy, 2019
Background The distribution of Pooideae species varies across Europe. Especially, Timothy is less represented in Southern than in Northern Europe. Since allergenic cross-reactivity between pollens from different grasses is only partial, grass pollen ...
Thierry Batard, Amparo Sanjuan, Laure Denis, Hélène Nguyen, Armelle Montagut, Joaquín Sastre, Sabina Rak, Jean F. Cuiné   +7 more
doaj   +1 more source

Molecular Attributes Associated With Refolding of Inclusion Body Proteins Using the Freeze–Thaw Method

Frontiers in Microbiology, 2021
Understanding the structure–function of inclusion bodies (IBs) in the last two decades has led to the development of several mild solubilization buffers for the improved recovery of bioactive proteins.
Priyank Singhvi, Juhi Verma, Neha Panwar, Neha Panwar, Tabiya Qayoom Wani, Akansha Singh, Md. Qudratullah, Arnab Chakraborty, Ankit Saneja, Debi P. Sarkar, Amulya K. Panda   +10 more
doaj   +1 more source

Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics

mAbs, 2020
Manufacturability of immunoglobulin G4 (IgG4) antibodies from the Chemistry, Manufacture, and Controls (CMC) perspective has received little attention during early drug discovery.
Zhiqiang Chen, Yueming Qian, Yuanli Song, Xuankuo Xu, Li Tao, Nesredin Mussa, Sanchayita Ghose, Zheng Jian Li   +7 more
doaj   +1 more source

Paternal products and by–products in Drosophila development [PDF]

Proceedings of the Royal Society of London. Series B: Biological Sciences, 1998
Tails of fertilizing spermatozoa persist throughout embryogenesis in Drosophila species and can be observed within the midguts of larvae after hatching. Throughout development, sperm proteins slowly diffuse or are stripped from the giant sperm tail residing within the embryo's anterior end.
S, Pitnick, T L, Karr
openaire   +2 more sources

Tumor growth inhibition modeling to support the starting dose for dacomitinib

CPT: Pharmacometrics & Systems Pharmacology, 2022
Dacomitinib is a second‐generation, irreversible EGFR tyrosine kinase inhibitor for first‐line treatment of patients with metastatic non‐small cell lung cancer and EGFR‐activating mutations.
Luke K. Fostvedt, Dana J. Nickens, Weiwei Tan, Kourosh Parivar   +3 more
doaj   +1 more source

Baseline risk factors associated with immune related adverse events and atezolizumab

Frontiers in Oncology, 2023
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer patients in the last decade, but immune-related adverse events (irAEs) pose significant clinical challenges.
Katrin Madjar, Rajat Mohindra, Gonzalo Durán-Pacheco, Rashad Rasul, Laurent Essioux, Vidya Maiya, G. Scott Chandler   +6 more
doaj   +1 more source

Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion

Drugs in R&D, 2019
Objective PF-06438179/GP1111 (PF-SZ-IFX) is an infliximab biosimilar. We evaluated the extended in-use physicochemical and biological stability of PF-SZ-IFX upon preparation for intravenous infusion. Methods Two batches of PF-SZ-IFX were reconstituted to
Maja Vimpolsek, Marie Gottar-Guillier, Emmanuel Rossy   +2 more
doaj   +1 more source